Conclusion: 5 years of adjuvant tamoxifen safely reduces 15-year risks of breast cancer recurrence and death. ER status was the only recorded factor importantly predictive of the proportional reductions. Hence, the absolute risk reductions produced by tamoxifen depend on the absolute breast cancer risks (after any chemotherapy) without tamoxifen.
PubMed 21802721 ↗Tamoxifen
Also known as Nolvadex
The short answer. More people than not who report on Tamoxifen say it helped (64% of 75). It is most often used for hormones: 98% of 49 reports say that improved. It is well studied — 479 meta-analyses on PubMed. The most common complaint is fatigue.
From 298 mentions in total — the rest didn't say how it went and aren't counted.
What Tamoxifen does, according to users
Of the people who reported each effect, the share who said it got better.
7 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 479 meta-analyses on PubMed ↗ · 1,597 randomized trials ↗
Conclusion: Aromatase inhibitors reduce recurrence rates by about 30% (proportionately) compared with tamoxifen while treatments differ, but not thereafter. 5 years of an aromatase inhibitor reduces 10-year breast cancer mortality rates by about 15% compared with 5 years of tamoxifen, hence by about 40% (proportionately) compared with no endocrine treatment.
PubMed 26211827 ↗Conclusion: Vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may improve some GSM symptoms in the short term. Few long-term data exist on efficacy, comparative effectiveness, tolerability, and safety of GSM treatments.
PubMed 39250810 ↗Conclusion: Additionally, nine studies developed, validated and tested novel assays for detecting key pharmacogenomically important variants.Conclusion: While pharmacogenomics research in Sri Lanka has made strides, more clinical studies and broader genomic research are needed. Overcoming challenges related to funding, public awareness and regional collaboration is essential to advance personalized medicine and improve therapeutic outcomes in Sri Lanka and South Asia.
PubMed 39540556 ↗684 human trials on ClinicalTrials.gov test Tamoxifen — 368 completed, 65 recruiting now. See all on ClinicalTrials.gov ↗
- ER Reactivation Therapy for Breast Cancer · Metastatic Breast Cancer · 2024
- Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion · BRCA Mutation, PALB2 Gene Mutation · 2026
- Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer · Breast Cancer, HER2-negative Breast Cancer · 2026
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Boxed warning (the FDA's strongest label warning): “For Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for Breast Cancer: Serious and life-threatening events associated with tamoxifen citrate in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary…”
1 recall of products named for Tamoxifen. Most recent:
- 2015-04-29 · Class II: Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were… record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
5,727 adverse-event reports mention Tamoxifen. Most often reported:
- Fatigue · 396
- Nausea · 351
- Diarrhoea · 278
- Arthralgia · 276
- Malignant neoplasm progression · 266
- Pain · 247
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
LiverTox rates Tamoxifen B — a highly likely cause of liver injury (12–50 published cases). LiverTox entry ↗
NIH has funded 105 research projects with Tamoxifen in the title, $80,239,010 in total (1985–2025). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Tamoxifen ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“Dosage 5 mg starting at week 2. I upped the dose to 10 mg mid cycle due to slightly feeling suppressed.”
“Nolva for me has decently bad side effects so I might switch it up next time.”
“I have never experienced a single side effect with Nolva and it has always worked.”
“This is now 2nd day on nolva and I swaer my balls are about back to normal. Energy is a bit better”
Tamoxifen compared
Other options for hormones
Sources
- User reports: 298 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate